{
    "paper_id": "e10a00df9101c78210ce70041a806ec18929c08c",
    "metadata": {
        "title": "Supplementary Appendix",
        "authors": []
    },
    "abstract": [
        {
            "text": "This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": ". Demographic characteristics and comorbidities stratified by symptom grouping\u2026\u2026\u2026\u2026\u2026\u2026.12 Table S3 . Symptoms ",
            "cite_spans": [
                {
                    "start": 99,
                    "end": 107,
                    "text": "Symptoms",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 88,
                    "end": 96,
                    "text": "Table S3",
                    "ref_id": null
                }
            ],
            "section": ""
        },
        {
            "text": "Details of our cohort from Facility A are presented in Figure 1 . There were 89 residents living in Facility A on March 3, the day the first positive resident was identified, and by March 13, there were 82 residents. There were no admissions to Facility A since March 3. Of the 82 residents living in Facility A on March 13; two were hospitalized earlier in the day, prior to the first point prevalence survey, one was not present (receiving hemodialysis offsite), three declined testing, and 76 completed the symptom screening and testing. By March 26, 57 residents were positive for SARS-CoV-2; 48 of these had participated in our point prevalence surveys, 8 residents were unavailable for point prevalence surveys but tested positive during hospitalizations, and 1 resident who declined to participate in the point prevalence survey tested positive post-mortem.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 55,
                    "end": 63,
                    "text": "Figure 1",
                    "ref_id": null
                }
            ],
            "section": "Cohort Description"
        },
        {
            "text": "At the time of the first point prevalence study, the nursing staff from Facility A provided information on a symptom screening form for each resident including date of birth, gender, unit and room number. The form required the nursing staff to complete a medical chart review for documentation of any preexisting conditions, including history of: chronic lung disease, diabetes mellitus, cardiovascular disease (e.g., congestive heart failure), cerebrovascular accident/stroke, renal disease, cognitive impairment, obesity, and current treatment with hemodialysis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Symptom Screening Form"
        },
        {
            "text": "Symptoms were assessed by nursing staff on all participating residents at both point prevalence surveys and for those asymptomatic with a positive test, one week following the last survey. The data collection tool assessed if the resident had any of the following in the preceding 14 days: typical symptoms such as fever, cough, shortness of breath, or atypical symptoms such as chills, myalgia (body aches), malaise (feeling generally unwell), sore throat, runny nose or congestion, confusion or sleepiness, dizziness, headache, diarrhea, and nausea and/or vomiting. For each symptom selected (except for fever or chills), the form requested information on whether that symptom was chronic (i.e., ongoing for more than 14 days) for that resident. For all symptoms selected, the form then asked if the symptom was new or worsened, and to provide the date of onset. The form then asked if the resident was still experiencing this symptom on the day of the survey, and if not, to list the date the symptom resolved.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Symptom Screening Form"
        },
        {
            "text": "At the time of the first point prevalence survey, clinicians interviewed residents to confirm symptoms reported by nursing staff on the screening tool. The outbreak investigation team used the electronic medical record to identify pre-existing conditions if not listed on the symptom screening form. At the conclusion of both point prevalence surveys, the outbreak investigation team reviewed the electronic medical record to corroborate symptoms onset dates for all patients with positive test results.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Symptom Screening Form"
        },
        {
            "text": "The most commonly reported symptom among residents with a positive SARS-CoV-2 test was cough (33%). Residents also reported malaise (13%), and fever (10%), although residents with negative SARS-CoV-2 tests also reported fever (14%), cough (14%), and malaise (11%) most frequently (Table S1 ).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 280,
                    "end": 289,
                    "text": "(Table S1",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "Symptom Screening Form"
        },
        {
            "text": "Characteristics, including age and pre-existing conditions, were also similar when positive residents were stratified by symptom status at time of test (Table S2 ). Among the 24 residents who were asymptomatic at the time of testing and developed symptoms in the subsequent week, the most commonly reported symptoms were fever, cough, and malaise (Table S3) .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 152,
                    "end": 161,
                    "text": "(Table S2",
                    "ref_id": "TABREF1"
                },
                {
                    "start": 347,
                    "end": 357,
                    "text": "(Table S3)",
                    "ref_id": null
                }
            ],
            "section": "Symptom Screening Form"
        },
        {
            "text": "Cognitive impairment was common among residents with both positive (58%) and negative tests (46%).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Symptom Screening Form"
        },
        {
            "text": "Of those with a positive test, similar proportions of residents who reported symptoms at the time of testing had cognitive impairment (62%), compared to those who did not report symptoms (56%).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Symptom Screening Form"
        },
        {
            "text": "For the initial point prevalence survey, nasopharyngeal (NP) and oropharyngeal (OP) swabs (if collected) were placed in the same viral transport media. For the follow-up survey, on March 19-20, 62 residents were tested and NP and OP swabs were placed in separate tubes and analyzed separately. Real-Time RT-PCR Diagnostic Panel (RNA copies /ul) was determined to be 100.5 and 100 using the QIAGEN EZ1 Advanced XL or DSP Viral RNA Mini Kit, respectively; at these concentrations, the CDC rRT-PCR panel identified N1 and N2 positive targets at a rate of 100% [2] . Additionally, the percent agreement of the CDC rRT-PCR diagnostic panel with a composite comparator was 100% (n=13, 95% CI: 77.2% -100%) for positive specimens and 100% (n=104, 95% CI; 96.4% -100%) for negative specimens [2] . 8 to 25.7) ). Similar to findings shown in Figure 2 in the manuscript, Ct values did not appear to be correlated with the days from symptom (typical or atypical) onset to testing ( Figure S1 ). Among twelve residents with two consecutive positive tests for SARS-CoV-2, symptom onset date did not appear to be associated with increases or decreases in serial Ct values ( Figure S2 ).",
            "cite_spans": [
                {
                    "start": 557,
                    "end": 560,
                    "text": "[2]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 784,
                    "end": 787,
                    "text": "[2]",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [
                {
                    "start": 790,
                    "end": 800,
                    "text": "8 to 25.7)",
                    "ref_id": null
                },
                {
                    "start": 833,
                    "end": 841,
                    "text": "Figure 2",
                    "ref_id": null
                },
                {
                    "start": 971,
                    "end": 980,
                    "text": "Figure S1",
                    "ref_id": null
                },
                {
                    "start": 1160,
                    "end": 1169,
                    "text": "Figure S2",
                    "ref_id": null
                }
            ],
            "section": "Specimen Testing"
        },
        {
            "text": "Specimens were shipped to CDC's laboratory for viral culture, where the rRT-PCR-positive specimens were used to inoculate Vero-CCL-81 cells (one culture not assessed). Cells showing cytopathic effect were used for SARS-CoV-2 rRT-PCR to confirm isolation and viral growth in culture. The mean Ct values for genetic marker N1 for samples positive by rRT-PCR with positive culture growth was lower than for those without (22.4 vs 30.6).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Culture and Sequencing"
        },
        {
            "text": "Nucleic acid was extracted from rRT-PCR positive specimens and amplified for subsequent Oxford Nanopore MinION sequencing [3] . Consensus sequences by nanopore sequencing were generated using minimap 2.17 and samtools 1.9. Phylogenetic trees were inferred with the Neighbor-Joining method using the Hasegawa-Kishino-Yano nucleotide substitution model with gamma-distributed rate variation among sites (HKY + G) with 500 bootstrap replicates using Geneious Prime (Biomatters, INC., San Diego, CA) and MEGA X [4] .",
            "cite_spans": [
                {
                    "start": 122,
                    "end": 125,
                    "text": "[3]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 507,
                    "end": 510,
                    "text": "[4]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Culture and Sequencing"
        },
        {
            "text": "Sequencing results for 39 positive primary specimens from 34 residents and resulted in nine closelyrelated sequences with 1 to 4 nucleotide (NT) difference compared to each other (Supplementary Table   S5 ). Sequences were submitted to Genbank and GISAID (Table S6 ). For 5 residents with two specimens sequenced, the first and specimen sequence were identical. Of the 34 residents, 27 fell into two clusters (sequence B and sequence H,) with 1 NT difference (Supplementary Table S3 ). All sequences are identical or highly similar to previously reported USA-WA sequences branching form USA-WA1/sequences from China (Supplementary Figure S3) .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 179,
                    "end": 204,
                    "text": "(Supplementary Table   S5",
                    "ref_id": null
                },
                {
                    "start": 255,
                    "end": 264,
                    "text": "(Table S6",
                    "ref_id": "TABREF2"
                },
                {
                    "start": 474,
                    "end": 482,
                    "text": "Table S3",
                    "ref_id": null
                },
                {
                    "start": 631,
                    "end": 641,
                    "text": "Figure S3)",
                    "ref_id": null
                }
            ],
            "section": "Culture and Sequencing"
        },
        {
            "text": "To evaluate facility transmission dynamics, residents with positive test results for SARS-CoV-2 were Table S4 ). The doubling time for all residents of King County with positive tests for SARS-CoV-2 was estimated using the same method and time period using counts reported through PHSKC COVID-19 data dashboard as 5.5 days (95%CI: 4.8, 6.7) [5] .",
            "cite_spans": [
                {
                    "start": 341,
                    "end": 344,
                    "text": "[5]",
                    "ref_id": "BIBREF5"
                }
            ],
            "ref_spans": [
                {
                    "start": 101,
                    "end": 109,
                    "text": "Table S4",
                    "ref_id": null
                }
            ],
            "section": "Facility A Transmission"
        },
        {
            "text": "Residents were mapped according to their room assignment and their infection onset date. Infection date is symptom onset date or test date for those asymptomatic at time of testing. Unit of residence appears to be associated with infection date, with the majority of unit one infections occurring first.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Facility A Transmission"
        },
        {
            "text": "Sequencing results identified most sequenced isolates from unit 1 and 2 were from one cluster (sequence H), while isolates from unit 4 were from the second cluster (sequence B, Figure S4 ). Figure S1 . Cycle threshold values relative to date of first evidence of any symptoms (typical or atypical).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 177,
                    "end": 186,
                    "text": "Figure S4",
                    "ref_id": "FIGREF6"
                },
                {
                    "start": 190,
                    "end": 199,
                    "text": "Figure S1",
                    "ref_id": null
                }
            ],
            "section": "Facility A Transmission"
        },
        {
            "text": "Shown are N1 target cycle threshold values and viral culture results for each resident's positive tests for SARS-CoV-2 shown by day since first evidence of fever, cough, or shortness of breath (N=53*). *Includes 42 residents with known onset dates for first reported symptoms; 11 residents have two specimens positive for SARS-CoV-2 included. One resident reported having experienced atypical symptoms in the 14 days preceding testing, but no onset date was listed. **Sequences A-I represent nine closely-related sequences from 34 residents with up to 4 nucleotide (NT) difference (see Figure S3 and Table S5 ) ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 586,
                    "end": 595,
                    "text": "Figure S3",
                    "ref_id": null
                },
                {
                    "start": 600,
                    "end": 608,
                    "text": "Table S5",
                    "ref_id": null
                }
            ],
            "section": "Tables and Figures"
        }
    ],
    "bib_entries": {
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Real-Time RT-qPCR Panel for Detection 2019-Novel Coronavirus",
            "authors": [],
            "year": 2020,
            "venue": "Centers for Disease Control and Prevention",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Centers for Disease Control and Prevention. 2019-Novel Coronavirus (2019-nCoV) Real-time rRT-PCR Diagnostic Panel",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "2019-nCoV) Real-time rRT-PCR Panel Primers and Probes",
            "authors": [],
            "year": 2020,
            "venue": "Centers for Disease Control and Prevention. 2019-Novel Coronavirus",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Molecular Evolutionary Genetics Analysis across Computing Platforms",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Kumar",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Stecher",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Knyaz",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Tamura",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Mega X",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Mol Biol Evol",
            "volume": "35",
            "issn": "6",
            "pages": "1547--1549",
            "other_ids": {
                "DOI": [
                    "10.1093/molbev/msy096"
                ]
            }
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "County Department of Health COVID-19 data dashboard: King County COVID-19 outbreak summary",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Seattle-King",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Facility A Transmission ............................................................................................................................. 6 Tables and Figures .............................................................................................................................Cycle threshold values relative to date of first evidence of any symptoms. ........................... Serial cycle threshold values for residents with two positive tests. ........................................ Phylogenetic tree of selected SARS-CoV2 genomes. ............................................................... Map of Facility A .................................................................................................................... 10 Table S1. Specific symptoms for residents of Facility A at time of testing ............................................. 11",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "reported at follow-up. ........................................................................................... 12 Table S4. Doubling Time. ........................................................................................................................ 13 Table S6. Genbank accession numbers and GISAID identification numbers ......................................... 14 References ....................................................................................................................................... 16",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Specimen collection and diagnostic testing were conducted in accordance with CDC guidelines for respiratory specimens [1]. The Washington State Public Health Laboratory performed one step real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) assay on all NP/OP combined samples from March 13 and all NP samples from March 19-20. In addition, 33 OP samples from March 19-20 were tested (15 OP samples sent to the lab were not tested). The limit of detection for the CDC 2019-nCoV",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "19-20, 62 residents were retested for SARS-CoV-2, including 49 who were negative on March 13. From this second point prevalence survey, 36 residents were positive, including 24 newly identified positives among the 49 who were negative as of March 13. Of the 33 residents from the second point prevalence study who had both NP and OP results available, six residents had discordant NP and OP tests; all six had a positive OP test and negative NP test. These residents were considered positive for the second point prevalence survey. Cycle threshold (Ct) values were reported for two genetic markers: N1, N2 [2] for 47 residents who tested positive during the point prevalence studies (i.e., not including the resident with a positive test result only from March 8). For residents with both NP and OP Ct values reported for the second point prevalence survey, we selected the swab with the lower Ct value. The median Ct values for each of the symptom status groups were similar (asymptomatic resident's median Ct value: 25.5 (Q1 to Q3: 25.3 to 31.1), presymptomatic: 23.1 (17.1 to 30.8), atypical symptoms: 25.3 (19.8 to 29.7), typical symptoms: 21.5 (19.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "identified from March 3 to March 26, including those tested in acute care settings and post-mortem. No admissions to Facility A occurred during this period. The daily growth rate was estimated using leastsquares regression of the log-transformed daily cumulative counts of residents positive for SARS-CoV-2, from March 3 through our second point prevalence survey, March 20. Doubling time was estimated as the natural log(2) divided by the daily growth rate. The daily growth rate was estimated as 0.204 (95% CI: 0.131, 0.278) and the doubling time among residents in this facility was estimated to be 3.4 days (95% CI: 2.5 to 5.3,",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "Serial cycle threshold values for the N1 target for 12 residents with two positive testsfirst evidence of fever, cough, or shortness of breath Phylogenetic tree of selected SARS-CoV2 genomes including 39 genomes from this study.Select full genome sequences available as of March 24, 2020 were included in this Neighbor-Joining tree. A) Polar tree layout of sequences analyzed. Blue branches indicate sequences from USA-WA and red branches indicate sequences from this study (USA-WA, nursing home). B)Branch view of USA-WA nursing home cases (red). The 39 genomes were from specimens of 34 residents. All 5 residents with 2 specimens had identical sequences from the first and second specimens.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "Map of residents of Facility A with positive tests for SARS-CoV-2. Shown here is a map of facility A denoting residents positive for SARS-CoV-2. Coloring of room indicates date of symptom onset*, and letter in room denotes the genetic sequence of isolates** from that room, double occupancy rooms are denoted by a dashed line *For asymptomatic or presymptomatic residents, onset is the date of the first positive test.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Specific symptoms for residents of Facility A at time of testing, by SARS-CoV-2 test results -Results include all residents present in facility March 13 and assented to screening. Facility-wide cohort symptom screens and testing performed on March 13 and March 19-20, 2020. Positive residents include those with at least one positive test from facility-wide cohort screening on March 13 and March 19-20 and one resident who was negative on March 13 but tested positive in unit-wide cohort screening on March 8.",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Demographic characteristics and comorbidities stratified by symptom grouping at time of SARS-CoV-2 test Table S3. Symptoms reported at 7-day follow-up among residents with a positive SARS-CoV-2 test who were asymptomatic at time of testing (N=27).Table S4. Number of residents of Facility A with a positive test for SARS-CoV-2 by date used to calculate doubling time.Table S5 Nucleotide differences between sequences among 39 genomes from this study. 39 genomes were sequenced from 34 residents; 5 residents had two specimens sequenced (which produced identical sequences)",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Genbank accession numbers and GISAID identification numbers for the 39 genomes sequenced in this study",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}